Xpectives News

In the News: Abuse-Deterrent Formulations Stirring Up the 2016 J.P. Morgan Pharmaceutical Conference

January 28, 2016 by Lily Stauffer0

Considered by many the Woodstock of pharmaceutical conferences, the 34th Annual J.P. Morgan Conference held in San Francisco January 11-13th lived up to its nickname. It was three days of non-stop presentations, meetings, business development opportunities, and endless potential for new partnerships. Among the attendees was a convergence of hedge fund investors, bankers, and pharmaceutical executives. Cara Therapeutics, a small public biotech company based in Shelton, Connecticut sparked particular interest, as they released their data for their new abuse-deterrent formulation peptide. Currently deep into phase II of clinical development, CR845 is groundbreaking in the world of analgesic painkillers, as it does not penetrate the blood-brain barrier; making it virtually impossible to abuse. Looking towards 2016, President and CEO Derek Chalmers was quoted as saying, “based on these encouraging findings, we plan to conduct a larger double-blind, placebo-controlled Phase 2b trial in 2016.” The company is hopeful that by early 2018, CR845 will be approved for the market and forever alter the use of opioid formulations.

For the official press release from Cara Therapeutics, click here.

Lily Stauffer

Leave a Reply

Your email address will not be published. Required fields are marked *